apomorphine has been researched along with liraglutide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dixit, TS; Elased, KM; Lucot, JB; Sharma, AN | 1 |
| Barkholt, P; Fabricius, K; Hansen, HH; Jelsing, J; Knudsen, LB; Mikkelsen, JD; Pyke, C; Vrang, N | 1 |
2 other study(ies) available for apomorphine and liraglutide
| Article | Year |
|---|---|
Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis.
Topics: Animals; Antipsychotic Agents; Apomorphine; Disease Models, Animal; Dopamine Agonists; Glucagon-Like Peptide 1; Liraglutide; Male; Mice; Psychotic Disorders; Pyrazines; Sitagliptin Phosphate; Statistics, Nonparametric; Triazoles | 2013 |
Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Body Weight; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopaminergic Neurons; Glucagon-Like Peptide-1 Receptor; Liraglutide; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |